Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13550147 | 0.89 | BRAF (0.47) | BRAFCAMK2DCSF1RIGF1RCDK1 | |
| SCHEMBL12123839 | 0.83 | BRAF (0.46) | BRAFCAMK2DCSF1RIGF1REGFR | |
| SCHEMBL12124052 | 0.82 | BRAF (0.45) | BRAFCAMK2DCSF1RIGF1REGFR | |
| SCHEMBL12120858 | 0.78 | BRAF (0.53) | BRAFCAMK2DCSF1RIGF1RCDK1 | |
| SCHEMBL12671538 | 0.76 | BRAF (0.50) | BRAFCAMK2DCSF1RIGF1RCDK1 | |
| SCHEMBL13534038 | 0.72 | SLC2A1 (0.38) | BRAFCAMK2DCSF1REGFRITK | |
| SCHEMBL16497192 | 0.72 | SLC2A1 (0.38) | BRAFCAMK2DCSF1REGFRITK | |
| SCHEMBL1845366 | 0.72 | PDPK1 (0.47) | BRAFCAMK2DCSF1R | |
| SCHEMBL1845368 | 0.72 | PDPK1 (0.47) | BRAFCAMK2DCSF1R | |
| SCHEMBL13534307 | 0.71 | PDPK1 (0.39) | BRAFCAMK2DCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321299-B1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-8637549-B2 | Pyridons as PDK1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2010007114-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007116-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | PDK2, PDK4, CCNH | BRAF 861/4885CAMK2D 1297/4885CSF1R 1006/4885 |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | PDK1, PDK2, PDK4 | BRAF 310/4885CAMK2D 777/4885CSF1R 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.